Given only data generated by a standard confounding graph with unobserved confounder, the Average Treatment Effect (ATE) is not identifiable. To estimate the ATE, a practitioner must then either (a) collect deconfounded data;(b) run a clinical trial; or (c) elucidate further properties of the causal graph that might render the ATE identifiable. In this paper, we consider the benefit of incorporating a large confounded observational dataset (confounder unobserved) alongside a small deconfounded observational dataset (confounder revealed) when estimating the ATE. Our theoretical results suggest that the inclusion of confounded data can significantly reduce the quantity of deconfounded data required to estimate the ATE to within a desired accuracy level. Moreover, in some cases -- say, genetics -- we could imagine retrospectively selecting samples to deconfound. We demonstrate that by actively selecting these samples based upon the (already observed) treatment and outcome, we can reduce sample complexity further. Our theoretical and empirical results establish that the worst-case relative performance of our approach (vs. a natural benchmark) is bounded while our best-case gains are unbounded. Finally, we demonstrate the benefits of selective deconfounding using a large real-world dataset related to genetic mutation in cancer.